Drug Trial Radar · NCT07617194
Study of AHB-171 in Chronic Hepatitis B Participants
Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
144
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Oct 8, 2027
Study completion Aug 14, 2028
Sponsor
- Lead sponsor
- AusperBio Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AHB-171 in participants with chronic hepatitis B (CHB). Study advancement to subsequent parts/cohorts will require satisfactory interim reviews of available cumulative safety data by the Safety Review Committees (SRC), using the safety criteria and review procedures described in the protocol.
Conditions
- Hepatitis B, Chronic
Interventions
AHB-171Drug
Injection
Placebo matching [Investigational Product]Drug
Injection
Nucleos(t)ide Analogue (NA)Drug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs) [Safety and Tolerability]Time frame: Up to 72 weeks
- The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: the maximum observed plasma concentration (Cmax) of AHB-171.Time frame: Up to 72 weeks
- The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: the area under the concentration-time curve extrapolated to infinity (AUCinf ) of AHB-171Time frame: Up to 72 weeks
- Incidence of clinically significant changes in Vital Signs [Safety and Tolerability]Time frame: Up to 72 weeks
- Incidence of clinically significant changes in cardiac parameters [Safety and Tolerability]Time frame: Up to 72 weeks
- Incidence of laboratory abnormalities [Safety and Tolerability]Time frame: Up to 72 weeks
- The plasma pharmacokinetic (PK) profile of AHB-171 and metabolites: area under the curve from the time of dosing to the last measurable concentration (AUClast) of AHB-171Time frame: Up to 72 weeks
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Queen Mary Hospital
Hong Kong, Hong Kong
New Zealand Clinical Research
Grafton, Auckland, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.